Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05007379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids

Study acronym: CARMA
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Study sites: 0 to 1
    • Study completion date: Sep 1, 2023 to Dec 1, 2027
    • Start date changed from estimate of Sep 1, 2021 to Nov 2, 2021
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study title shortened, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.
Trial Details
NCT Number NCT05007379
Lead Sponsor Centre Oscar Lambret
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov